Ditte Bork Iversen

Ditte Bork Iversen

Auto-generated profile, based on publicly available information

Ditte Bork Iversen

Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2022 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Open access
DIDitte B. Iversen
Ditte B. Iversen
NANanna Elman Anderse
Nanna Elman Anderse
ADAnn‐Cathrine Dalgård Dunvald
Ann‐Cathrine Dalgård Dunvald
APAnton Pottegård
Anton Pottegård
TSTore Bjerregaard Stage
Tore Bjerregaard Stage
Safe and effective use of drugs requires an understanding of metabolism and transport. We identified the 100 most prescribed drugs in six countries and conducted a literature search on in vitro data to assess contribution of Phase I and II enzymes and drug transporters to metabolism and transport.Eighty‐nine of the 100 drugs undergo drug metabolism or are known substrates for drug transporters. Phase I enzymes are involved in metabolism of 67 drugs, while Phase II enzymes mediate metabolism of 18 drugs. CYP3A4/5 is the most important Phase I enzyme involved in metabolism of 43 drugs followed by CYP2D6 (23 drugs), CYP2C9 (23 drugs), CYP2C19 (22 drugs), CYP1A2 (14 drugs) and CYP2C8 (11 drugs). More than half of the drugs (54 drugs) are known substrates for drug transporters. P‐glycoprotein (P‐gp) is known to be involved in transport of 30 drugs, while breast cancer resistance protein (BCRP) facilitates transport of 11 drugs. A considerable proportion of drugs are subject to a combination of Phase I metabolism, Phase II metabolism and/or drug transport.We conclude that the majority of the most frequently prescribed drugs depend on drug metabolism or drug transport. Thus, understanding variability of drug metabolism and transport remains a priority.

9 December 2022 in Pain
Verified
Journal Article
Closed access
CMChristina Mortensen
Christina Mortensen
KSKarina Dahl Steffensen
Karina Dahl Steffensen
ESEmma Simonsen
Emma Simonsen
KHKamille Herskind
Kamille Herskind
JMJonna Madsen
Jonna Madsen
TSTore Bjerregaard Stage
Tore Bjerregaard Stage
Paclitaxel-induced peripheral neuropathy (PIPN) is a barrier to effective cancer treatment and impacts quality of life among patients with cancer. We used a translational approach to assess the utility of neurofilament light chain (NFL) as a biomarker of PIPN in a human cell model and in patients with ovarian cancer. We measured NFL in medium from human induced pluripotent stem cell–derived sensory neurons (iPSC-SNs) exposed to paclitaxel. Serum NFL (sNFL) levels were quantified in 190 patients with ovarian cancer receiving paclitaxel/carboplatin chemotherapy at baseline and after each of the following 2 or 6 cycles. Adverse outcomes related to PIPN were retrospectively obtained, and Cox regression model was performed with different sNFL cut-offs after first cycle. The apparent elimination half-life of sNFL was estimated in patients who discontinued paclitaxel. Paclitaxel neurotoxicity in iPSC-SNs was accompanied by NFL release in a concentration-dependent manner (P < 0.001, analysis of variance). Serum NFL levels increased substantially in patients during paclitaxel/carboplatin chemotherapy with considerable interindividual variability. Patients with sNFL >150 pg/mL after first cycle had increased risk to discontinue paclitaxel early (unadjusted HR: 2.47 [95% CI 1.16-5.22], adjusted HR: 2.25 [95% CI: 0.88-5.79]). Similar trends were shown for risk of severe PIPN and paclitaxel dose reduction because of PIPN. The median elimination half-life of sNFL was 43 days (IQR 27-82 days). Neurofilament light chain constitutes an objective biomarker of neurotoxicity in iPSC-SNs and in ovarian cancer patients with high sNFL predicting PIPN-related adverse outcomes. If prospectively validated, NFL can be used to study PIPN and may guide clinical decision making and personalize treatment with paclitaxel.

1 June 2022 in Clinical and Translational Science
Verified
Journal Article
Open access
ADAnn‐Cathrine Dalgård Dunvald
Ann‐Cathrine Dalgård Dunvald
DIDitte Bork Iversen
Ditte Bork Iversen
ASAndreas Ludvig Ohm Svendsen
Andreas Ludvig Ohm Svendsen
KAKatrine Agergaard
Katrine Agergaard
IKIda Berglund Kuhlmann
Ida Berglund Kuhlmann
TSTore Bjerregaard Stage
Tore Bjerregaard Stage
Pharmacokinetics is the cornerstone of understanding drug absorption, distribution, metabolism, and elimination. It is also the key to describing variability in drug response caused by drug‐drug interactions (DDIs), pharmacogenetics, impaired kidney and liver function, etc. This tutorial aims to provide a guideline and step‐by‐step tutorial on essential considerations when designing clinical pharmacokinetic studies and reporting results. This includes a comprehensive guide on how to conduct the statistical analysis and a complete code for the statistical software R. As an example, we created a mock dataset simulating a clinical pharmacokinetic DDI study with 12 subjects who were administered 2 mg oral midazolam with and without an inducer of cytochrome P450 3A. We provide a step‐by‐step guide to the statistical analysis of this clinical pharmacokinetic study, including sample size/power calculation, descriptive statistics, noncompartmental analyses, and hypothesis testing. The different analyses and parameters are described in detail, and we provide a complete R code ready to use in supplementary files. Finally, we discuss important considerations when designing and reporting clinical pharmacokinetic studies. The scope of this tutorial is not limited to DDI studies, and with minor adjustments, it applies to all types of clinical pharmacokinetic studies. This work was done by early career researchers for early career researchers. We hope this tutorial may help early career researchers when getting started on their own pharmacokinetic studies. We encourage you to use this as an inspiration and starting point and continuously evolve your statistical skills.

8 June 2023 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
DIDitte B. Iversen
Ditte B. Iversen
ADAnn‐Cathrine Dalgård Dunvald
Ann‐Cathrine Dalgård Dunvald
DJDaniel M. Jespersen
Daniel M. Jespersen
FNFlemming Nielsen
Flemming Nielsen
KBKim Brøsen
Kim Brøsen
TSTore Bjerregaard Stage
Tore Bjerregaard Stage
Flucloxacillin is a widely used antibiotic. It is an agonist to the nuclear receptor PXR that regulates the expression of cytochrome P450 (CYP) enzymes. Treatment with flucloxacillin reduces warfarin efficacy and plasma concentrations of tacrolimus, voriconazole, and repaglinide. We conducted a translational study to investigate if flucloxacillin induces CYP enzymes. We also investigated if flucloxacillin induces its own metabolism as an autoinducer. We performed a randomized, unblinded, two‐period, cross‐over, clinical pharmacokinetic cocktail study. Twelve healthy adults completed the study. They ingested 1 g flucloxacillin 3 times daily for 31 days, and we assessed the full pharmacokinetics of the Basel cocktail drugs on days 0, 10, and 28, and plasma concentrations of flucloxacillin on days 0, 9, and 27. The 3D spheroid of primary human hepatocytes (PHHs) were exposed to flucloxacillin (concentration range: 0.15–250 μM) for 96 hours. Induction of mRNA expression, protein abundance, and enzyme activity of CYP enzymes were assessed. Flucloxacillin treatment reduced the metabolic ratio of midazolam (CYP3A4), (geometric mean ratio (GMR) 10 days (95% confidence interval (CI)): 0.75 (0.64–0.89)) and (GMR 28 days (95% CI): 0.72 (0.62–0.85)). Plasma concentrations of flucloxacillin did not change during 27 days of treatment. Flucloxacillin caused concentration‐dependent induction of CYP3A4 and CYP2B6 (mRNA, protein, and activity), CYP2C9 (mRNA and protein), CYP2C19 (mRNA and activity), and CYP2D6 (activity) in 3D spheroid PHH. In conclusion, flucloxacillin is a weak inducer of CYP3A4, which may lead to clinically relevant drug–drug interactions for some narrow therapeutic range drugs that are substrates of CYP3A4.

1 May 2021 in The American Journal of Medicine
Verified
Journal Article
Closed access
DIDitte B. Iversen
Ditte B. Iversen
MHMaja Hellfritzsch
Maja Hellfritzsch
TSTore Bjerregaard Stage
Tore Bjerregaard Stage
RARune M. Aabenhus
Rune M. Aabenhus
BLBent S. Lind
Bent S. Lind
APAnton Pottegård
Anton Pottegård

10 January 2026 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
AMAnas Mohammad
Anas Mohammad
DIDitte Bork Iversen
Ditte Bork Iversen
NRNete Lundager Klokker Rausgaard
Nete Lundager Klokker Rausgaard
CKChristina Kruuse
Christina Kruuse
DBDagmar Beier
Dagmar Beier
LPLanfranco Pellesi
Lanfranco Pellesi
Cyclic guanosine monophosphate (cGMP)-mediated mechanisms plays a role in migraine pathophysiology. Sildenafil, a phosphodiesterase type 5 inhibitor, incre